Core Insights - Plus Therapeutics, Inc. has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will chair the Audit Committee and serve on the Compensation Committee [1][2] - Guse brings over 30 years of experience in financial, transactional, and operational roles, including significant positions at Atossa Therapeutics, Inc. and DDC Enterprise Ltd. [2][3] - The company is focused on developing targeted radiotherapeutics for central nervous system cancers, with products like REYOBIQ™ and CNSide, aiming to enhance clinical outcomes [4] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in targeted radiotherapeutics for challenging CNS cancers [4] - The company combines image-guided local beta radiation with targeted drug delivery approaches, advancing a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the online availability of new data on its lead compound REYOBIQ™ (rhenium Re186 obisbemeda) in an abstract for both an oral presentation and a poster to be presented at the Nuclear Medicine and Neurooncology conference to be held May 9-10, 2025 ...

Therefore, the Zacks rating upgrade for Plus basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) DELAWARE 33-0827593 (State or Other Jurisdiction ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call. Before we begin, we want to advise you that over the course of the call, including any question-and-answer session, for ...

Core Insights - Plus Therapeutics reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.51, representing an earnings surprise of -31.37% [1] - The company generated revenues of $1.41 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 6.49% and showing a slight increase from $1.31 million a year ago [2] - Plus shares have increased by approximately 27.8% since the beginning of the year, contrasting with a -2.9% decline in the S&P 500 [3] Company Outlook - The future performance of Plus Therapeutics will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - Current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $1.7 million, while for the current fiscal year, it is -$1.60 on revenues of $5.4 million [7] - The estimate revisions trend for Plus is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Indivior PLC, is expected to report quarterly earnings of $0.22 per share, reflecting a year-over-year decline of 40.5% [9]

PLUS THERAPEUTICS, Inc. (PSTV) Q4 2024 Earnings Conference Call March 27, 2025 05:00 PM ET Company Participants Sherry - Conference Call ModeratorDr. Mark Hedrick - President and Chief Executive OfficerAndrew Sims - Chief Financial OfficerEdward Wu - Accedient Capital (Caller)Jason Colbert - Deep World Capital (Caller - via Lindsay)Sean Lee - HC Wainwright (Caller) Dr. Mark Hedrick Final remarks, so after Q&A, just turn it back to me for a few seconds, please. Sherry Good afternoon, ladies and gentlemen. We ...

Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights UPCOMING EXPECTED EVENTS AND MILESTONES FULL YEAR 2024 FINANCIAL RESULTS • Completed ReSPECT-LM Phase 1 single dose administration trial and determined the maximum feasible and recommended Phase 2 doses. Additional details can be found here • Presented positive ReSPECT-LM Phase 1 interim data for LM at the 2024 SNO Annual Conference. Additional details can be found here • Presented posit ...

The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. “ ...

Shares of Plus Therapeutics, Inc. (PSTV) were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV’s lead therapeutic candidate, rhenium Re186 obisbemeda.Plus Therapeutics’ request for a proprietary name review for Reyobiq must be submitted after the new drug application (NDA) is filed for the candidate.Per the company, going forward, all communications related to the USAN-adopted and INN-proposed rhenium Re18 ...